MHB018A not checked
Minghui Pharmaceutical (Hangzhou) Ltd
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “6 subcutaneous injections of MHB018A placebo once every 4 weeks (q4w)”In the company’s words, NCT06989918 on ClinicalTrials.gov
- Tested for
- Thyroid Eye Disease (TED) (3 trials), Thyroid Eye Disease, TED (2 trials), Thyroid Associated Ophthalmopathies
- Main trialPhase 3
- “The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered q4W for 6 months, in comparison to placebo, in the treatment of participants suffering from active TED.”In the company’s words, NCT06989918 on ClinicalTrials.gov
Other drugs for Thyroid Eye Disease (TED)
- IBI311Innovent · Phase 3
- ZL-1109Zai Lab (Shanghai) Co., Ltd. · Phase 3
- KHN939Beijing Kanghong Biological Medicine Co., Ltd. · Phase 3
- LinsitinibSling Therapeutics, Inc. · Astellas · Phase 3
- TeprotumumabAmgen · Phase 3
- VRDN-003Viridian Therapeutics, Inc. · Phase 3
Coming up6
- DecPhase 3 trial completes · ClinicalTrials.gov
- 31 Aug 2027Phase 3 trial completes · ClinicalTrials.gov
- Jul 2028Phase 3 trial completes · ClinicalTrials.gov
- Jul 2028Phase 3 trial completes · ClinicalTrials.gov
- 31 Jan 2029Phase 3 trial completes · ClinicalTrials.gov
- Jan 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Dec 2026 | MHB018A Treatment in Patients With Active Thyroid Eye Disease | |
| Phase 3Active, not recruiting | 31 Aug 2027 | MHB018A Treatment in Patients With Chronic Thyroid Eye Disease | |
| Phase 3Recruiting | Jul 2028 | Treatment of Chronic Thyroid Eye Disease With MHB018A | |
| Phase 3Recruiting | Jul 2028 | Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study | |
| Phase 3Recruiting | 31 Jan 2029 | Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease | |
| Phase 3Not yet recruiting | Jan 2030 | Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026